SM
KPTI icon

Sabby Management’s Karyopharm Therapeutics KPTI Stock Holding History

Sabby Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-24
Closed -$210K – 98
2019
Q1 		$210K Buy
+24
New +$2.66K 0.1% 49

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Sabby Management's KPTI Position: Q2 2019 in Review

Sabby Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2019, closing a stake of 1,667 shares — an estimated $146K sold.

Sabby Management first reported a position in KPTI in Q1 2019 and held it in 1 quarter. The position peaked at $146K in Q1 2019. 103 funds tracked by Wall St. Rank hold KPTI as of Q2 2019.

  • Sabby Management reported no remaining Karyopharm Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Sabby Management sold 1,667 Karyopharm Therapeutics shares in Q2 2019, an estimated $146K.
  • Sabby Management first reported a position in Karyopharm Therapeutics in Q1 2019 and held it in 1 quarter.
  • Sabby Management's Karyopharm Therapeutics position peaked at $146K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2019.

Based on Sabby Management's 13F filing for Q2 2019, filed 14 Aug 2019.